

DAFTAR PUSTAKA

- Amedee RG, Miller AJ.2006. *Sinus anatomy and function*. In: Bailey BJ, Johnson JT, Newlands SD, eds. Head & Neck Surgery – Otolaryngology. 4th ed. Vol 1. Philadelphia: Lippincott Williams & Wilkins. p. 3218
- Amsen D, de Visser KE, Town T. 2009. *Approaches to Determine Expression of Inflammatory Cytokines* In: Inflammation and Cancer, Methods in Molecular Biology. Vol 511. Humana Press, a part of Springer Science. P. 107-142
- Aygun N, 2005. *Radiology of Nasal Cavity and Paranasal Sinuses*. Cummnings Otolaryngology Head and Neck Surgery 4th ed. Vol 2. Elsevier Mosby Philadelphia. p;1153-6
- Bachert, C., Han, JK., Desrosiers, M., Hellings, PW., et. al. 2019. *Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): result from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials*. Published online September 19, [https://doi.org/10.1016/S0140-6736\(19\)31881-1](https://doi.org/10.1016/S0140-6736(19)31881-1)
- Benninger, MS & Gottschall, J .2006, *Rhinosinusitis : Clinical Presentation and Diagnosis in Sinusitis From Microbiology to Management* edited by Itzhak Brook , Georgetown University School of Medicine Washington, D.C., U.S.A.New York. p; 39-52
- Beule AG. 2010. *Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses*. GMS current topics in otorhinolaryngology – head and neck surgery. p; 1-24.

- Bose S, Grammer LC, Peters AT. 2016. *Infectious Chronic Rhinosinusitis*. J Allergy Clin Immunol Pract 4(4) p; 584-589.
- Castejon GL, David B.,2011. *Understanding the mechanism of IL-1b secretion*. Elsevier, hh 189-195.
- Cheng YK, Lin C, Chang WC, et.al. 2006. *Increased Prevalance of Interleukin 1- receptor antagonist gene polymorphismn in patients with chronic rhinosinusitis*. In : Arch Otolaryngol head neck surg. Vol 136, American Medical Association, hh 285-290
- Deng J., Chen, F., Lai, YY., et. al. 2017. *Lack of additional effects of long-term, low-dose clarithromycin combined treatment compared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial*. International Forum of Allergy & Rhinology. Vol.00, No.0, pp: 1-7
- Dinarello, CA. 2011. *Interleukin-1 in pathogenesis and treatment of inflammatory disease*. American Sosity Of Hematology.
- Endam ML,Cormier C, Bosse Y, et. All, 2010. *Association of IL1A, IL1B, and TNF Gene Polymorphisms with chronic Rhinosinusitis with and without nasal Polyposis*. In : Arch Otolaryngol head neck surg. Vol 136, American Medical Association, hh 187-191.
- Fokken WJ, Lund VJ, Muloll J, Bachert C. 2012, 'European Position Paper On Rhinosinusitis And Nasal Polip', In *Rhinology Journal Of European And International Sociaties*, Vol 50 (Suppl 23), p; 1-198.
- Fokken WJ, Lund VJ, Muloll J, Bachert C. 2020, 'European Position Paper On Rhinosinusitis And Nasal Polip', In *Rhinology Journal Of European And International Sociaties*, Vol 50 (Suppl 23), hh. 1-198.

Hwang PH & Abdalkhani A. 2009, *Embryology, Anatomy and Physiology of the nose and Paranasal Sinuses*, In Snow JB, Wackym PA, editors, Ballenger's Otorhinolaryngology Head and Neck surgery 17ed, Connecticut ,BC Decker Inc, hh. 455-463. Soetjipto D, 2012

Hsueh, WD., Conley, DB., Kim, H., et. al. 2013. International Forum of Allergy & Rhinology. Vol. 3, No.4, pp: 307-14

Kabiraj A. et al., 2015. *Principle and Techniques of Immunohistochemistry – a Review*. Int J Biol Med Res, 6(3), p;5204–5210.

Kato A, 2014. *Immunopathology of Chronic Rhinosinusitis*. Allergology International. p; 1-8

Lal, D., Round AB., Divekar, R., et. al. 2016. *Gender-specific differences in chronic rhinosinusitis patient electing endoscopic sinus surgery*. International Forum of Allergy & Rhinology, Vol. 6, No. 3, pp: 278-86

Lal,D., Hopkins C., and Divekar, RD. 2018. *SNOT-22 based clusters in chronic rhinosinusitis without nasal polyposis exhibit distinct endotypic and prognostic differences*. International Forum of Allergy & Rhinology. Vol.8, No. 7,pp: 797-805

Langereis, JD., Oudijk JD., Schweizer,RC., et.al. 2011. *Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1 β synthesis by human neutrophils*. European Respiratory Journal. Vol 32, No. 2, pp: 406-15

Leung R, Conley D, Kern R & Chandra R. 2011, *Obstruction is Not Associated with Adjacent Sinus Disease in Chronic Rhinosinusitis with Polyps*. AJRA, In Press

Leung RM, Walsh WE, Kern RC, 2014, *Sinonasal Anatomy and Physiology*. In : Jhonson JT, Rosen CA, editors. *Bailey's Head and Neck Surgery Otolaryngology. Fifth Edition*, Philadelphia, Lippincot Williams & Wilkins, p;359-369.

Levina H, Clemente MP. 2005, *Surgical Anatomy of the Paranasal Sinus in : Sinus Surgery Endoscopic and Microscopic Approaches*, Thieme Medical Publishers, New York, p; 10-25.

Li CW, Shi L, Zhang KK, Li TY, Lin ZB, Lim MK, et al. 2011. *Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis*. J Allergy Clin Immunol 127(3): 765-72.

Liu, T., Zhou YT., Wang, LQ., et. al. 2019. *NOD-like receptor family, pyrin domain containing 3 (NLRP3) contributes to inflammation, pyroptosis, and mucin production in human airway epithelium on rhinovirus infection*. American Academy of Allergy, Asthma & Immunology. Pp: 1-20

Min, HJ., Kim, SJ., Kim, TH., et.al. 2015. *Level of Secreted HMGB1 Correlates with Severity of Inflammation in Chronic Rhinosinusitis*. The Laryngoscope, pp: 225- 30

Min YG and Lee KS, 2000. *The Role of Cytokines in Rhinosinusitis*. The Korean Academy of Medical Sciences . p;. 255-259

Mohamad, S., Hamid, SSA., Azlina A., et. al. 2019. *Association of IL-1 gene polymorphisms with chronic rhinosinusitis with and without nasal polyp*. Asia Pacific Allergy. pp: 1-10

Mulyarjo, 2004, *Diagnosis Klinik Rhinosinusitis dalam Naskah Lengkap Perkembangan Terkini Diagnosis dan Penatalaksanaan Rhinosinusitis*, Bagian Ilmu Kesehatan THT FK Unair/ RSU Dr. Soetomo, Surabaya, hh. 17-24

Mustafa, M, Patawari, P, Iftikhar, HM, Shimmi, SC, Hussain, SS & Sien, MM 2015, *Acute and Chronic Rhinosinusitis, Pathophysiology and Treatment*, International Journal of Pharmaceutical Sience Intervention, hh. 4(2) : 30-36.

Naclerio RM and Chaaban MR. 2014. Immunology and Allergy In : Jhonson JT, Rosen CA, editors. *Bailey's Head and Neck Surgery Otolaryngology. Fifth Edition*, Philadelphia, Lippincot Williams & Wilkins, hh. 379-411

Patel ZM and Hwang PH 2014, *Nonpolypoid Rhinosinusitis: Pathogenesis, Diagnosis, Staging, and Treatment*. In : Jhonson JT, Rosen CA, editors. *Bailey's Head and Neck Surgery Otolaryngology. Fifth Edition*, Philadelphia, Lippincot Williams & Wilkins, p; 535-49

Plewka, D., Grzanka, A., Drzewiecka., Plewka A., et. al. 2017. *Differential expression of tumor necrosis factor α , interleukin 1 β , nuclear factor κB in nasal mucosa among chronic rhinosinusitis patients with and without polyps*. Advances in Dermatology and Allergology, pp: 199-206

Punagi, Q 2008, *Pola Penyakit Sub Bagian Rinologi di RS Pendidikan Makassar Periode 2003-2008*, Bagian Ilmu Kesehatan THT-KL, Fakultas Kedokteran Universitas Hasanuddin

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. *Clinical Practice Guideline (Update) : Adult Sinusitis.Otolaryngology-Head and Neck Surgery*. 2015, hh: 152(2S):S1-S39.

Saber A, Hussain R, Nakka SS, Hugusson S. 2019. Effect of *Staphylococcus aureus* in NLRP3 inflammasome, caspase 1 and IL-1B expression in the nasal epithelial celss in chronic rhinosinusitis. *Archives of Otolaryngology and Rhinology* . 5(1) : 001-007

- Savastano, V., Bertin, S., Vittori, T., et.al. 2014. *Evaluation of Chronic Rhinosinusitis Management Using The SNOT-22 in adult cystic fibrosis patients*. Eur Rev Med Pharmacol Sci. 18(14), pp: 1985-9
- Scheckenbach, K and Wagenmann, M. 2016. *Cytokine Patterns and Endotype in Acute and Chronic Rhinosinusitis*. New York: Springer. pp: 3-8
- Schlosser, RJ., Mulligan, JK., Hyer, JM., et. al. 2016. *Mucous Cytokine Levels in Chronic Rhinosinusitis-Associated Olfactory Loss*. JAMA Otolaryngology-Head & Neck Surgery. pp: 731-37
- Shalini S, Dorstyn L, Dawar S, Kumar S. 2014. *Old, New and emerging functions of caspases In Cell Death and Differentiation*. Macmillan Publishers Lt. p; 1-14
- Shi, JB., Fu, QL., Zhang, H., et. al. 2015. *Epidemiology of Chronic Rhinosinusitis: result from a cross-sectional survey in seven Chinese cities*. European Journal of Allergy and Clinical Immunology. pp: 533-39
- Soetjipto D, Dharmabakti U, Mangunkusumo E & Utama, R, 2012, *Functional Endoscopic Sinus Surgery di Indonesia*, Panel Ahli THT Indonesia, hh. 1-52
- Soetjipto D dan Wardani RS, 2006. Penatalaksanaan Sinusitis. Dalam Guideline Penyakit THT-KL, PERHATI-KL INDONESIA
- Standring S. 2016. Nose, Nasal Cavity, Paranasal Sinuses In: *Gray's Anatomy*. Ed. 41st. Elsevier. hh. 556-789
- Sujana S. 2017. Hubungan Interluekin-17A, Skor Lund Mackay dan SNOT 20 pada penderita Rinosinusitis Kronik dengan dan tanpa polip. Tesis, Makassar :PPDS IK THT-KL UNHAS

- Triola, S. 2019. *Pengaruh Cuci Hidung dengan NaCl 0,9% Terhadap Ekspresi Gen IL-1Beta dan TNF-Alpha Mukosa Hidung Penderita Rinosinusitis Kronis di RSUP Dr M Djamil Padang*. Health & Medical Journal 1(2) pp: 17-27
- Utami, AD. 2019. Identifikasi Mikrobiom Pada Penderita Rinosinusitis Kronis Dengan dan Tanpa Polip. Tesis, Makassar :PPDS IK THT-KL UNHAS
- Watelet JB. 2004. *Fibrogenic growth factors and metalloproteinases during wound healing after sinus surgery*. Available from: lib.ugent.be/fulltxt/RUG01/000/804/293/RUG01-000804293_2010_0001_AC.pdf Accessed September 13, 2019
- Walsh, WE and Kern RC, 2006, *Sinonasal Anatomy, function and evaluation*. In: Bailey BJ, Johnson JT, editors. *Head and Neck Surgery-otolaryngology*. 4th ed, Philadelphia, Lippincott Williams & Wilkins, hh. 307-18
- Younis, RT and Ahmed, J. 2016. *Predicting Revision Sinus Surgery in Allergic Fungal and Eosinophilic Mucin Chronic Rhinosinusitis*. The Laryngoscope, pp: 1-5
- Zhang Y, Gevaert E, Wang X, et al. 2017. *Chronic Rhinosinusitis in Asia*. American Academy Of Alergy, Asthma & Immunology.
- Zimmermann, KS. 2008. *Transmucosal nasal drug delivery*. Basel: University of Basel; pp:120

Lampiran 1. Data Dasar Hasil Penelitian

| Record number | Kode | Jenis Kelamin | Usia | IL 1-β | SKOR LMK | Obstruksi Nasi | Rinorea/ PND | Facial Pain | Gangguan Penghidu | Status RSK |
|---------------|---------|---------------|------|--------|----------|----------------|--------------|-------------|-------------------|-------------|
| 1 | LA 1NP | Laki-laki | 27 | 82 | 10 | 4 | 7 | 5 | 0 | Tanpa Polip |
| 2 | LA2NP | Perempuan | 35 | 56 | 5 | 3 | 5 | 0 | 0 | Tanpa Polip |
| 3 | LA 3NP | Perempuan | 22 | 77 | 4 | 2 | 5 | 0 | 0 | Tanpa Polip |
| 4 | LA 4NP | Perempuan | 46 | 90.6 | 9 | 4 | 6 | 6 | 0 | Tanpa Polip |
| 5 | LA 5NP | Perempuan | 26 | 78.4 | 4 | 3 | 6 | 0 | 0 | Tanpa Polip |
| 6 | LA 6NP | Perempuan | 47 | 91.8 | 1 | 4 | 5 | 4 | 1 | Tanpa Polip |
| 7 | LA 7NP | Perempuan | 23 | 81 | 16 | 5 | 4 | 4 | 0 | Tanpa Polip |
| 8 | LA 8NP | Perempuan | 47 | 95.6 | 11 | 2 | 4 | 5 | 0 | Tanpa Polip |
| 9 | LA 9NP | Perempuan | 53 | 94.6 | 9 | 4 | 4 | 5 | 0 | Tanpa Polip |
| 10 | LA 10NP | Perempuan | 46 | 90 | 21 | 5 | 7 | 6 | 2 | Tanpa Polip |
| 11 | LA 11NP | Perempuan | 47 | 86.6 | 3 | 2 | 4 | 0 | 0 | Tanpa Polip |
| 12 | LA 12NP | Laki-laki | 56 | 89.2 | 7 | 2 | 5 | 0 | 0 | Tanpa Polip |
| 13 | LA 13NP | Perempuan | 35 | 83.4 | 16 | 4 | 6 | 5 | 2 | Tanpa Polip |
| 14 | LA 14NP | Perempuan | 43 | 75.6 | 4 | 2 | 4 | 0 | 0 | Tanpa Polip |
| 15 | LA 15NP | Perempuan | 23 | 70.8 | 3 | 1 | 5 | 0 | 0 | Tanpa Polip |
| 16 | LA 16NP | Laki-laki | 29 | 71.8 | 8 | 1 | 6 | 0 | 0 | Tanpa Polip |
| 17 | LA 17NP | Laki-laki | 28 | 73.8 | 7 | 4 | 4 | 0 | 0 | Tanpa Polip |
| 18 | LA 18NP | Perempuan | 25 | 88.8 | 2 | 0 | 5 | 3 | 0 | Tanpa Polip |
| 19 | LA 19NP | Laki-laki | 28 | 86.4 | 3 | 1 | 2 | 4 | 0 | Tanpa Polip |
| 20 | LA 20NP | Perempuan | 19 | 79.2 | 2 | 2 | 4 | 2 | 0 | Tanpa Polip |
| 21 | LA 21NP | Perempuan | 19 | 82.2 | 9 | 0 | 5 | 0 | 0 | Tanpa Polip |
| 22 | LA 22NP | Perempuan | 66 | 90.6 | 8 | 0 | 4 | 5 | 0 | Tanpa Polip |
| 23 | LA 23NP | Laki-laki | 26 | 89 | 8 | 2 | 7 | 6 | 0 | Tanpa Polip |
| 24 | LA 24NP | Perempuan | 19 | 87.6 | 7 | 3 | 5 | 4 | 0 | Tanpa Polip |
| 25 | LA 25NP | Perempuan | 36 | 91.8 | 4 | 4 | 4 | 5 | 0 | Tanpa Polip |
| 26 | LA 1P | Laki-laki | 57 | 5.8 | 24 | 7 | 7 | 2 | 5 | Polip |
| 27 | LA2P | Laki-laki | 57 | 30 | 21 | 5 | 7 | 4 | 3 | Polip |
| 28 | LA 3P | Perempuan | 58 | 28 | 13 | 0 | 4 | 2 | 0 | Polip |
| 29 | LA 4P | Laki-laki | 20 | 33 | 21 | 4 | 8 | 2 | 2 | Polip |
| 30 | LA 5P | Perempuan | 51 | 12.6 | 12 | 0 | 4 | 2 | 0 | Polip |
| 31 | LA 6P | Perempuan | 71 | 41 | 14 | 0 | 6 | 3 | 0 | Polip |
| 32 | LA 7P | Perempuan | 29 | 33 | 17 | 2 | 4 | 3 | 0 | Polip |
| 33 | LA8P | Perempuan | 27 | 10.6 | 12 | 0 | 4 | 0 | 0 | Polip |
| 34 | LA 9P | Laki-laki | 65 | 15 | 5 | 0 | 5 | 0 | 0 | Polip |
| 35 | LA 10P | Laki-laki | 42 | 22 | 22 | 4 | 7 | 4 | 2 | Polip |
| 36 | LA 11P | Laki-laki | 57 | 4 | 11 | 0 | 5 | 0 | 0 | Polip |
| 37 | LA 12P | Perempuan | 19 | 71 | 11 | 0 | 6 | 5 | 0 | Polip |
| 38 | LA 13P | Laki-laki | 26 | 20 | 24 | 5 | 8 | 2 | 3 | Polip |
| 39 | LA 15P | Laki-laki | 34 | 44 | 23 | 5 | 8 | 3 | 4 | Polip |
| 40 | LA 16P | Laki-laki | 30 | 36.4 | 17 | 0 | 7 | 0 | 0 | Polip |
| 41 | LA 17P | Perempuan | 35 | 26.8 | 22 | 5 | 7 | 0 | 4 | Polip |
| 42 | LA 18P | Perempuan | 27 | 22.8 | 9 | 0 | 5 | 0 | 0 | Polip |
| 43 | LA 19P | Perempuan | 35 | 73.8 | 7 | 0 | 5 | 4 | 0 | Polip |
| 44 | LA 21P | Perempuan | 27 | 76 | 20 | 4 | 5 | 5 | 0 | Polip |
| 45 | LA 22P | Laki-laki | 29 | 43.8 | 14 | 0 | 6 | 2 | 0 | Polip |
| 46 | LA 26P | Laki-laki | 30 | 54 | 20 | 5 | 6 | 4 | 2 | Polip |
| 47 | LA 27P | Perempuan | 20 | 36.8 | 17 | 0 | 5 | 0 | 0 | Polip |
| 48 | LA 29P | Perempuan | 31 | 136 | 22 | 7 | 8 | 8 | 3 | Polip |
| 49 | LA 30P | Laki-laki | 17 | 75.4 | 18 | 2 | 7 | 5 | 0 | Polip |
| 50 | LA 31P | Laki-laki | 61 | 67 | 15 | 0 | 6 | 4 | 0 | Polip |

Lampiran 2. Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR.
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, M.Med., Ph.D., Sp.GK. TELP : 081241850858. 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 688/UN4.6.4.5.31 / PP36 / 2020

Tanggal: 26 Oktober 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|--|--|---|---------------------------|
| No Protokol | UH20080403 | No Sponsor Protokol | |
| Peneliti Utama | dr. Lidya Allo Datu Turupadang | Sponsor | |
| Judul Peneliti | Hubungan Ekspresi Interleukin-1 β (IL-1 β) Dengan Skor Lund-Mackay Pada Penderita Rinosinusitis Kronis Dengan Dan Tanpa Polip | | |
| No Versi Protokol | 2 | Tanggal Versi | 19 Oktober 2020 |
| No Versi PSP | 2 | Tanggal Versi | 19 Oktober 2020 |
| Tempat Penelitian | RS Universitas Hasanuddin dan RSUP Dr.Wahidin Sudirohusodo Makassar | | |
| Jenis Review | <input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal | Masa Berlaku 26 Oktober 2020 sampai 26 Oktober 2021 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | | |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 3. Dokumentasi Penelitian




Sampel Penelitian



Anti body Primer IL-1 β



Proses Pengerjaan Imunihistokimia IL-1 β



CT-Scan Sinus Paranasal Potongan Coronal Tanpa Kontras pada RSK dengan polip



CT-Scan Sinus Paranasal Potongan Coronal Tanpa Kontras pada RSK tanpa polip

Lampiran 4. Uji Statistik SPSS

A. Karakteristik Responden

1. Jenis Kelamin

Case Processing Summary

| | Cases | | | | | |
|-----------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Jenis Kelamin * | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| Keterangan | | | | | | |

Jenis Kelamin * Keterangan Crosstabulation

| Jenis Kelamin | Laki-laki | | Keterangan | | Total |
|---------------|-----------|------------------------|-------------|--------|--------|
| | | | Tanpa Polip | Polip | |
| Jenis Kelamin | Laki-laki | Count | 6 | 13 | 19 |
| | | % within Jenis Kelamin | 31.6% | 68.4% | 100.0% |
| | | % within Keterangan | 24.0% | 52.0% | 38.0% |
| | | % of Total | 12.0% | 26.0% | 38.0% |
| | | | | | |
| | Perempuan | Count | 19 | 12 | 31 |
| | | % within Jenis Kelamin | 61.3% | 38.7% | 100.0% |
| | | % within Keterangan | 76.0% | 48.0% | 62.0% |
| | | % of Total | 38.0% | 24.0% | 62.0% |
| | | | | | |
| Total | | Count | 25 | 25 | 50 |
| | | % within Jenis Kelamin | 50.0% | 50.0% | 100.0% |
| | | % within Keterangan | 100.0% | 100.0% | 100.0% |
| | | % of Total | 50.0% | 50.0% | 100.0% |
| | | | | | |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|--------------------|----|-----------------------------------|----------------------|----------------------|
| Pearson Chi-Square | 4.160 ^a | 1 | .041 | | |

| | | | | | | |
|------------------------------------|-------|---|------|------|--|------|
| Continuity Correction ^b | 3.056 | 1 | .080 | | | |
| Likelihood Ratio | 4.235 | 1 | .040 | | | |
| Fisher's Exact Test | | | | .079 | | .040 |
| Linear-by-Linear Association | 4.076 | 1 | .043 | | | |
| N of Valid Cases | 50 | | | | | |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.50.

b. Computed only for a 2x2 table

Symmetric Measures

| | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|--|-------|--|----------------------------|--------------------------|
| Nominal by Nominal Contingency Coefficient | .277 | | | .041 |
| Interval by Interval Pearson's R | -.288 | .134 | -2.087 | .042 ^c |
| Ordinal by Ordinal Spearman Correlation | -.288 | .134 | -2.087 | .042 ^c |
| N of Valid Cases | 50 | | | |

a. Not assuming the null hypothesis.

b. Using the asymptotic standard error assuming the null hypothesis.

c. Based on normal approximation.

2. Usia

Case Processing Summary

| | Cases | | | | | |
|-------------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Usia * Keterangan | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |

usia* Keterangan Crosstabulation

| Usia | 18-28 | Count | Keterangan | | Total |
|------|-------|---------------------|-------------|-------|--------|
| | | | Tanpa Polip | Polip | |
| Usia | 18-28 | Count | 12 | 8 | 20 |
| | | % within usia | 60.0% | 40.0% | 100.0% |
| | | % within Keterangan | 48.0% | 32.0% | 40.0% |
| | | % of Total | 24.0% | 16.0% | 40.0% |
| | 29-39 | Count | 4 | 9 | 13 |
| | | % within usianewbg | 30.8% | 69.2% | 100.0% |
| | | % within Keterangan | 16.0% | 36.0% | 26.0% |
| | | % of Total | 8.0% | 18.0% | 26.0% |

| | | | | | |
|--|-------|---------------------|--------|--------|--------|
| | 40-50 | Count | 6 | 1 | 7 |
| | | % within usia | 85.7% | 14.3% | 100.0% |
| | | % within Keterangan | 24.0% | 4.0% | 14.0% |
| | | % of Total | 12.0% | 2.0% | 14.0% |
| | >50 | Count | 3 | 7 | 10 |
| | | % within usia | 30.0% | 70.0% | 100.0% |
| | | % within Keterangan | 12.0% | 28.0% | 20.0% |
| | | % of Total | 6.0% | 14.0% | 20.0% |
| | Total | Count | 25 | 25 | 50 |
| | | % within usia | 50.0% | 50.0% | 100.0% |
| | | % within Keterangan | 100.0% | 100.0% | 100.0% |
| | | % of Total | 50.0% | 50.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) |
|------------------------------|--------------------|----|-----------------------------------|
| Pearson Chi-Square | 7.895 ^a | 3 | .048 |
| Likelihood Ratio | 8.387 | 3 | .039 |
| Linear-by-Linear Association | .727 | 1 | .394 |
| N of Valid Cases | 50 | | |

a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 3.50.

Symmetric Measures

| | | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|----------------------|-------------------------|-------|--|----------------------------|--------------------------|
| Nominal by Nominal | Contingency Coefficient | .369 | | | .048 |
| Interval by Interval | Pearson's R | .122 | .138 | .850 | .399 ^c |
| Ordinal by Ordinal | Spearman Correlation | .131 | .141 | .915 | .365 ^c |
| N of Valid Cases | | 50 | | | |

- a. Not assuming the null hypothesis.
- b. Using the asymptotic standard error assuming the null hypothesis.
- c. Based on normal approximation.

3. Skor Lund-Mackay

Case Processing Summary

| | Cases | | | | | |
|------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| SkorLMK * | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| Keterangan | | | | | | |

SkorLMK* Keterangan Crosstabulation

| | | Keterangan | | Total |
|-------------|---------------------|-------------|--------|--------|
| | | Tanpa Polip | Polip | |
| SkorLMK <12 | Count | 22 | 7 | 29 |
| | % within SkorLMK | 75.9% | 24.1% | 100.0% |
| | % within Keterangan | 88.0% | 28.0% | 58.0% |
| | % of Total | 44.0% | 14.0% | 58.0% |
| >12 | Count | 3 | 18 | 21 |
| | % within SkorLMK | 14.3% | 85.7% | 100.0% |
| | % within Keterangan | 12.0% | 72.0% | 42.0% |
| | % of Total | 6.0% | 36.0% | 42.0% |
| Total | Count | 25 | 25 | 50 |
| | % within SkorLMK | 50.0% | 50.0% | 100.0% |
| | % within Keterangan | 100.0% | 100.0% | 100.0% |
| | % of Total | 50.0% | 50.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|------------------------------------|---------------------|----|-----------------------------------|----------------------|----------------------|
| Pearson Chi-Square | 18.473 ^a | 1 | .000 | | |
| Continuity Correction ^b | 16.092 | 1 | .000 | | |
| Likelihood Ratio | 20.035 | 1 | .000 | | |
| Fisher's Exact Test | | | | .000 | .000 |
| Linear-by-Linear Association | 18.103 | 1 | .000 | | |
| N of Valid Cases | 50 | | | | |

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10.50.

b. Computed only for a 2x2 table

Symmetric Measures

| | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|--|-------|--|----------------------------|--------------------------|
| | | | | |

| | | | | | |
|----------------------|-------------------------|------|------|-------|-------------------|
| Nominal by Nominal | Contingency Coefficient | .519 | | | .000 |
| Interval by Interval | Pearson's R | .608 | .110 | 5.303 | .000 ^c |
| Ordinal by Ordinal | Spearman Correlation | .608 | .110 | 5.303 | .000 ^c |
| N of Valid Cases | | 50 | | | |

- a. Not assuming the null hypothesis.
 b. Using the asymptotic standard error assuming the null hypothesis.
 c. Based on normal approximation.

Case Processing Summary

| | Cases | | | | | |
|--------------------------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Obstruksi Nasi * Keterangan | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| Rinore * Keterangan | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| Facial pain * Keterangan | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| Gangguan penghidu * Keterangan | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |

4. Obstruksi Nasi

Obstruksi Nasi* Keterangan

Crosstab

| | | Keterangan | | Total | |
|-----------------------|-----------|---------------------|--------|--------|--|
| | | Tanpa Polip | Polip | | |
| Obstruksi Nasi | tidak ada | Count | 3 | 3 | |
| | | % within H1-new | 50.0% | 50.0% | |
| | | % within Keterangan | 12.0% | 12.0% | |
| | | % of Total | 6.0% | 6.0% | |
| | ringan | Count | 13 | 3 | |
| | | % within H1-new | 81.3% | 18.8% | |
| | | % within Keterangan | 52.0% | 12.0% | |
| | | % of Total | 26.0% | 6.0% | |
| | sedang | Count | 9 | 13 | |
| | | % within H1-new | 40.9% | 59.1% | |
| | | % within Keterangan | 36.0% | 52.0% | |
| | | % of Total | 18.0% | 26.0% | |
| | berat | Count | 0 | 6 | |
| | | % within H1-new | 0.0% | 100.0% | |
| | | % within Keterangan | 0.0% | 24.0% | |
| | | % of Total | 0.0% | 12.0% | |
| Total | | Count | 25 | 25 | |
| | | % within H1-new | 50.0% | 50.0% | |
| | | % within Keterangan | 100.0% | 100.0% | |

| | % of Total | 50.0% | 50.0% | 100.0% |
|--|------------|-------|-------|--------|
|--|------------|-------|-------|--------|

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) |
|------------------------------|---------------------|----|-----------------------------------|
| Pearson Chi-Square | 12.977 ^a | 3 | .005 |
| Likelihood Ratio | 15.787 | 3 | .001 |
| Linear-by-Linear Association | 6.907 | 1 | .009 |
| N of Valid Cases | 50 | | |

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 3.00.

Symmetric Measures

| | | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|----------------------|-------------------------|-------|--|----------------------------|--------------------------|
| Nominal by Nominal | Contingency Coefficient | .454 | | | .005 |
| Interval by Interval | Pearson's R | .375 | .127 | 2.807 | .007 ^c |
| Ordinal by Ordinal | Spearman Correlation | .405 | .127 | 3.069 | .004 ^c |
| N of Valid Cases | | 50 | | | |

- a. Not assuming the null hypothesis.
- b. Using the asymptotic standard error assuming the null hypothesis.
- c. Based on normal approximation.

5. Rinore

Rinore * Keterangan

Crosstab

| Rinore | Ringan | Count | Keterangan | | Total |
|--------|--------|---------------------|-------------|-------|--------|
| | | | Tanpa Polip | Polip | |
| Ringan | sedang | Count | 1 | 0 | 1 |
| | | % within H2new | 100.0% | 0.0% | 100.0% |
| | | % within Keterangan | 4.0% | 0.0% | 2.0% |
| | | % of Total | 2.0% | 0.0% | 2.0% |
| berat | berat | Count | 21 | 15 | 36 |
| | | % within H2new | 58.3% | 41.7% | 100.0% |
| | | % within Keterangan | 84.0% | 60.0% | 72.0% |
| | | % of Total | 42.0% | 30.0% | 72.0% |
| Total | | Count | 25 | 25 | 50 |

| | | | |
|---------------------|--------|--------|--------|
| % within H2new | 50.0% | 50.0% | 100.0% |
| % within Keterangan | 100.0% | 100.0% | 100.0% |
| % of Total | 50.0% | 50.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) |
|------------------------------|--------------------|----|-----------------------------------|
| Pearson Chi-Square | 5.769 ^a | 2 | .056 |
| Likelihood Ratio | 6.367 | 2 | .041 |
| Linear-by-Linear Association | 5.640 | 1 | .018 |
| N of Valid Cases | 50 | | |

a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is .50.

Symmetric Measures

| | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|--|-------|--|----------------------------|--------------------------|
| Nominal by Nominal Contingency Coefficient | .322 | | | .056 |
| Interval by Interval Pearson's R | .339 | .120 | 2.499 | .016 ^c |
| Ordinal by Ordinal Spearman Correlation | .337 | .123 | 2.482 | .017 ^c |
| N of Valid Cases | 50 | | | |

- a. Not assuming the null hypothesis.
- b. Using the asymptotic standard error assuming the null hypothesis.
- c. Based on normal approximation.

6. Facial Pain

Facial Pain* Keterangan

Crosstab

| | | | Keterangan | | Total |
|-------------|-----------|---------------------|-------------|--------|--------|
| | | | Tanpa Polip | Polip | |
| Facial Pain | tidak ada | Count | 0 | 3 | 3 |
| | | % within H3New | 0.0% | 100.0% | 100.0% |
| | | % within Keterangan | 0.0% | 12.0% | 6.0% |
| | | % of Total | 0.0% | 6.0% | 6.0% |
| | ringan | Count | 5 | 9 | 14 |
| | | % within H3New | 35.7% | 64.3% | 100.0% |

| | | | | |
|--------|------------------------|--------|--------|--------|
| | % within Keterangan | 20.0% | 36.0% | 28.0% |
| | % of Total | 10.0% | 18.0% | 28.0% |
| sedang | Count | 18 | 9 | 27 |
| | % within H3New | 66.7% | 33.3% | 100.0% |
| | % within Keterangan | 72.0% | 36.0% | 54.0% |
| | % of Total | 36.0% | 18.0% | 54.0% |
| berat | Count | 2 | 4 | 6 |
| | % within H3New | 33.3% | 66.7% | 100.0% |
| | % within Keterangan | 8.0% | 16.0% | 12.0% |
| | % of Total | 4.0% | 8.0% | 12.0% |
| Total | Count | 25 | 25 | 50 |
| | % within H3New | 50.0% | 50.0% | 100.0% |
| | % within Keterangan | 100.0% | 100.0% | 100.0% |
| | % of Total | 50.0% | 50.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) |
|------------------------------|--------------------|----|---|
| Pearson Chi-Square | 7.810 ^a | 3 | .050 |
| Likelihood Ratio | 9.056 | 3 | .029 |
| Linear-by-Linear Association | 2.234 | 1 | .135 |
| N of Valid Cases | 50 | | |

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 1.50.

Symmetric Measures

| | | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|----------------------|-------------------------|-------|--|-------------------------------|-----------------------------|
| Nominal by Nominal | Contingency Coefficient | .368 | | | .050 |
| Interval by Interval | Pearson's R | -.214 | .134 | -1.514 | .137 ^c |
| Ordinal by Ordinal | Spearman Correlation | -.208 | .143 | -1.475 | .147 ^c |
| N of Valid Cases | | 50 | | | |

a. Not assuming the null hypothesis.

b. Using the asymptotic standard error assuming the null hypothesis.

c. Based on normal approximation.

7. Gangguan Penghidu

Gangguan Penghidu * Keterangan

Crosstab

| | | | Keterangan | | Total |
|--------------------------|-----------|---------------------|-------------|--------|--------|
| | | | Tanpa Polip | Polip | |
| Gangguan Penghidu | Tidak ada | Count | 18 | 13 | 31 |
| | | % within H4New | 58.1% | 41.9% | 100.0% |
| | | % within Keterangan | 72.0% | 52.0% | 62.0% |
| | | % of Total | 36.0% | 26.0% | 62.0% |
| | ringan | Count | 7 | 5 | 12 |
| | | % within H4New | 58.3% | 41.7% | 100.0% |
| | | % within Keterangan | 28.0% | 20.0% | 24.0% |
| | | % of Total | 14.0% | 10.0% | 24.0% |
| | sedang | Count | 0 | 5 | 5 |
| | | % within H4New | 0.0% | 100.0% | 100.0% |
| | | % within Keterangan | 0.0% | 20.0% | 10.0% |
| | | % of Total | 0.0% | 10.0% | 10.0% |
| | berat | Count | 0 | 2 | 2 |
| | | % within H4New | 0.0% | 100.0% | 100.0% |
| | | % within Keterangan | 0.0% | 8.0% | 4.0% |
| | | % of Total | 0.0% | 4.0% | 4.0% |
| Total | Count | | 25 | 25 | 50 |
| | | % within H4New | 50.0% | 50.0% | 100.0% |
| | | % within Keterangan | 100.0% | 100.0% | 100.0% |
| | | % of Total | 50.0% | 50.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymptotic Significance (2-sided) |
|------------------------------|--------------------|----|-----------------------------------|
| Pearson Chi-Square | 8.140 ^a | 3 | .043 |
| Likelihood Ratio | 10.849 | 3 | .013 |
| Linear-by-Linear Association | 5.597 | 1 | .018 |
| N of Valid Cases | 50 | | |

a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is 1.00.

Symmetric Measures

| | Value | Asymptotic Standardized Error ^a | Approximate T ^b | Approximate Significance |
|--|-------|--|----------------------------|--------------------------|
| | | | | |

| | | | | | | |
|----------------------|-------------------------|------|------|-------|--|-------------------|
| Nominal by Nominal | Contingency Coefficient | .374 | | | | .043 |
| Interval by Interval | Pearson's R | .338 | .105 | 2.488 | | .016 ^c |
| Ordinal by Ordinal | Spearman Correlation | .279 | .130 | 2.013 | | .050 ^c |
| N of Valid Cases | | 50 | | | | |

- a. Not assuming the null hypothesis.
- b. Using the asymptotic standard error assuming the null hypothesis.
- c. Based on normal approximation.

B. Analisa Interleukin (IL 1-β) pada RSK tanpa polip dan dengan polip

Case Processing Summary

| Keterangan | | Cases | | | | | |
|------------|-------------|-------|---------|---------|---------|-------|---------|
| | | Valid | | Missing | | Total | |
| | | N | Percent | N | Percent | N | Percent |
| IL 1-β | Tanpa Polip | 25 | 100.0% | 0 | 0.0% | 25 | 100.0% |
| | Polip | 25 | 100.0% | 0 | 0.0% | 25 | 100.0% |

Descriptives

| | Keterangan | Statistic | Std. Error |
|--------|-------------|----------------------------------|-------------|
| IL 1-β | Tanpa Polip | Mean | 1.81818 |
| | | 95% Confidence Interval for Mean | Lower Bound |
| | | | 79.5995 |
| | | | Upper Bound |
| | | | 87.1045 |
| | | 5% Trimmed Mean | 84.0378 |
| | | Median | 86.4000 |
| | | Variance | 82.644 |
| | | Std. Deviation | 9.09089 |
| | | Minimum | 56.00 |
| | | Maximum | 95.60 |
| | | Range | 39.60 |
| | | Interquartile Range | 12.60 |
| | | Skewness | -1.180 |
| | | Kurtosis | .464 |
| Polip | | Mean | 1.887 |
| | | 95% Confidence Interval for Mean | Lower Bound |
| | | | 5.92677 |
| | | | Upper Bound |
| | | 5% Trimmed Mean | 38.1489 |
| | Median | | 33.0000 |

| | | |
|---------------------|----------|------|
| Variance | 878.164 | |
| Std. Deviation | 29.63384 | |
| Minimum | 4.00 | |
| Maximum | 136.00 | |
| Range | 132.00 | |
| Interquartile Range | 39.50 | |
| Skewness | 1.473 | .464 |
| Kurtosis | 3.077 | .902 |

Tests of Normality

| | Keterangan | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|--------|-------------|---------------------------------|----|------|--------------|----|------|
| | | Statistic | df | Sig. | Statistic | df | Sig. |
| IL 1-β | Tanpa Polip | .151 | 25 | .143 | .914 | 25 | .038 |
| | Polip | .176 | 25 | .044 | .879 | 25 | .007 |

a. Lilliefors Significance Correction

Mann-Whitney Test

Ranks

| | Keterangan | N | Mean Rank | Sum of Ranks |
|--------|-------------|----|-----------|--------------|
| IL 1-β | Tanpa Polip | 25 | 36.38 | 909.50 |
| | Polip | 25 | 14.62 | 365.50 |
| | Total | 50 | | |

Test Statistics^a

| | IL 1-β |
|------------------------|---------|
| Mann-Whitney U | 40.500 |
| Wilcoxon W | 365.500 |
| Z | -5.278 |
| Asymp. Sig. (2-tailed) | .000 |

a. Grouping Variable:

Keterangan

C. Analisa skor Lund-Mackay pada RSK tanpa polip dan dengan polip

Case Processing Summary

| | Keterangan | Cases | | | | | |
|----------|-------------|-------|---------|---------|---------|-------|---------|
| | | Valid | | Missing | | Total | |
| | | N | Percent | N | Percent | N | Percent |
| SKOR LMK | Tanpa Polip | 25 | 100.0% | 0 | 0.0% | 25 | 100.0% |
| | Polip | 25 | 100.0% | 0 | 0.0% | 25 | 100.0% |

Descriptives

| | Keterangan | Statistic | Std. Error |
|--|------------|-----------|------------|
|--|------------|-----------|------------|

| | | | | |
|----------|-------------|----------------------------------|-------------|--------|
| SKOR LMK | Tanpa Polip | Mean | 7.64 | .950 |
| | | 95% Confidence Interval for Mean | Lower Bound | 5.68 |
| | | | Upper Bound | 9.60 |
| | | 5% Trimmed Mean | | 7.27 |
| | | Median | | 7.00 |
| | | Variance | | 22.573 |
| | | Std. Deviation | | 4.751 |
| | | Minimum | | 2 |
| | | Maximum | | 21 |
| | | Range | | 19 |
| | | Interquartile Range | | 6 |
| | | Skewness | | 1.174 |
| | | Kurtosis | | .464 |
| Polip | Polip | Mean | 16.44 | 1.096 |
| | | 95% Confidence Interval for Mean | Lower Bound | 14.18 |
| | | | Upper Bound | 18.70 |
| | | 5% Trimmed Mean | | 16.63 |
| | | Median | | 17.00 |
| | | Variance | | 30.007 |
| | | Std. Deviation | | 5.478 |
| | | Minimum | | 5 |
| | | Maximum | | 24 |
| | | Range | | 19 |
| | | Interquartile Range | | 10 |
| | | Skewness | | -.379 |
| | | Kurtosis | | .464 |

Tests of Normality

| | Keterangan | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|----------|-------------|---------------------------------|----|-------|--------------|----|------|
| | | Statistic | df | Sig. | Statistic | df | Sig. |
| SKOR LMK | Tanpa Polip | .147 | 25 | .169 | .892 | 25 | .012 |
| | Polip | .142 | 25 | .200* | .948 | 25 | .231 |

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Mann-Whitney Test

Ranks

| | Keterangan | N | Mean Rank | Sum of Ranks |
|----------|-------------|----|-----------|--------------|
| SKOR LMK | Tanpa Polip | 25 | 15.78 | 394.50 |
| | Polip | 25 | 35.22 | 880.50 |
| | Total | 50 | | |

Test Statistics^a

| | SKOR LMK |
|------------------------|----------|
| Mann-Whitney U | 69.500 |
| Wilcoxon W | 394.500 |
| Z | -4.722 |
| Asymp. Sig. (2-tailed) | .000 |

a. Grouping Variable: Keterangan

D. Analisa Hubungan ekspresi interleukin IL 1-β dan Skor LMK

Case Processing Summary

| | Cases | | | | | |
|----------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| IL 1-β | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |
| SKOR LMK | 50 | 100.0% | 0 | 0.0% | 50 | 100.0% |

Descriptives

| | | Statistic | Std. Error |
|----------|----------------------------------|-------------|------------|
| IL 1-β | Mean | 62.0520 | 4.32099 |
| | 95% Confidence Interval for Mean | Lower Bound | 53.3686 |
| | | Upper Bound | 70.7354 |
| | 5% Trimmed Mean | | 62.4133 |
| | Median | | 73.8000 |
| | Variance | | 933.549 |
| | Std. Deviation | | 30.55404 |
| | Minimum | | 4.00 |
| | Maximum | | 136.00 |
| | Range | | 132.00 |
| | Interquartile Range | | 53.85 |
| | Skewness | | -.293 |
| SKOR LMK | Kurtosis | | .337 |
| | Mean | | -.718 |
| | 95% Confidence Interval for Mean | Lower Bound | .662 |
| | | Upper Bound | 12.04 |
| | 5% Trimmed Mean | | .954 |
| | Median | | 10.12 |
| | Variance | | 13.96 |
| | Std. Deviation | | 11.93 |
| | Minimum | | 11.00 |
| | Maximum | | 45.509 |
| | Range | | 6.746 |

| | | |
|---------------------|--------|------|
| Interquartile Range | 10 | |
| Skewness | .260 | .337 |
| Kurtosis | -1.170 | .662 |

Tests of Normality

| | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|----------|---------------------------------|----|------|--------------|----|------|
| | Statistic | Df | Sig. | Statistic | df | Sig. |
| IL 1-β | .193 | 50 | .000 | .917 | 50 | .002 |
| SKOR LMK | .114 | 50 | .116 | .938 | 50 | .011 |

a. Lilliefors Significance Correction

b.

Correlations

| | | | IL 1-β | SKOR LMK |
|----------------|----------|-------------------------|---------|----------|
| Spearman's rho | IL 1-β | Correlation Coefficient | 1.000 | -.403** |
| | | Sig. (2-tailed) | . | .004 |
| | | N | 50 | 50 |
| | SKOR LMK | Correlation Coefficient | -.403** | 1.000 |
| | | Sig. (2-tailed) | .004 | . |
| | | N | 50 | 50 |

**. Correlation is significant at the 0.01 level (2-tailed).